Gen9 Obtains $21,000,000 New Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    500 Technology Square 1st Floor Cambridge, MA 01239
  • Company Description
    Synthetic Biology is poised to modernize trillion dollar industries by introducing genes that program microorganisms to produce pharmaceuticals, biofuels and chemicals. A small number of Gen9’s current production tools generate sufficient DNA content to, in principle, replace the world’s current annual output of synthetic genes.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Gen9 will use these funds to further invest in product development and to expand the commercial infrastructure for its synthetic biology business. As part of this investment.
  • M&A Terms
  • Venture Investor
    Agilent Technologies

Trending on Xconomy